Navigation Links
Palmetto GBA Selected as Subcontractor for CMS' Enterprise System Development Project
Date:10/23/2007

of BlueCross BlueShield of South Carolina. Palmetto GBA's principal business is providing administrative services for the Medicare health benefit program. Palmetto GBA and BlueCross BlueShield of South Carolina are independent licensees of the Blue Cross and Blue Shield Association.


'/>"/>
SOURCE Palmetto GBA
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Saw Palmetto Extract No Good In Improving Prostate Health
2. Hospital Selected to ‘25 Most Influential’ List in Radiology in 206
3. Six Towns in India Selected for Eco-City Project
4. New Computerized Imaging Systems Help In Better Dental Treatment Planning
5. Passive smoking affects respiratory system
6. Early Warning System For Breast Cancer
7. Gene connected to Multi-System disorder discovered
8. Anthrax hammers immune system
9. Reviving the Immune System
10. Painkilling Patch As Effective As Intravenous Delivery Systems
11. Wrestling found To Be Good for the Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...Jan. 8 The Alliance for...poses the new marketing campaigns by Wal-Mart, Sto...vide free prescribed antibiotics to customers. The...ll actually lead to increased costs in the form of...ce. While the public,s need for affordable health...
(Date:1/8/2009)...Jan. 8 A study released this week ...fering from multiple chronic diseases shines a muc...ealth care system to one that focuses on primary a...ive Medicine, the leader in disease prevention. ...h/20080506/NETU129LOGO ) , , The study, condu...
(Date:1/8/2009)...ia Assembly Member Tom Torlakson Introduces AB 89 ...wswire/ -- Today, Lung Cancer Alliance-Californi...Torlakson (D-11th District) for his continued lead...g for lung cancer research. For the third consecu... research is being considered in the California Le...
(Date:1/8/2009)...quick to condemn hurtful comments, study suggests ...- Many people overestimate how strongly they would... , Sixty-three percent of study participants at...er for an experiment with a white person rather th...acist comments about the black person when he left...
Breaking Medicine News(10 mins):Health News:Antibiotics as Loss Leaders? 2Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:Many Turn Blind Eye to Racism 2
...en from 55 countries who will be the fourth Intern... four-day international congress titled "WWH-2005"...st time in South Asia. The earlier meetings were h...de Janeiro (1999) and Stockholm (2002). Among its ...
...sing the cholesterol level in blood.High level of ... in moderate amounts, can lead to serious health r...n of University College London examined 199 health...how individuals react to stress and whether their ...
...s have successfully treated nerve damage in mice b...stem cells, and hope to treat patients with an inj...n future.// The results of the new research sugges...ervous axon growth and functional recovery after n...
..., the families of more than 1,200 children, whose ...nts' knowledge ,will each receive Compensations.//...eal announced recently ,in the United Kingdom. Th...ht the cases involving organ-retention at 146 hosp...
Other Medicine News:Health News:Delhi To Host International Women’s Congress From Nov 2 2Health News:Stem Cells From Hair Follicle To Repair Nerve Damage 2Health News:Organ Scandals Compensation And The Aftermath 2
(Date:1/8/2009)...ated at the initial dose in an ongoing Phase Ib tr...line after three days , , Conference Call Today...re-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nas...st cohort of an ongoing Phase Ib clinical trial of...ide polymerase inhibitor. ANA598 was very well-to...
(Date:1/7/2009)...n., Jan. 7 Scientists h...high likelihood of relapse in children with acute ...hers caution that further research is needed to de... IKAROS, lead to leukemia relapse, the findings ...tic tests to assess the risk of treatment failure....
(Date:1/7/2009)...d., Jan. 7 ImQuest Life Sciences a... application to the Food and Drug Administration t...rimidinedione HIV inhibitor IQP-0410. ImQuest anti...rst quarter of 2009. IQP-0410 is a novel small mol...onnucleoside reverse transcriptase inhibitor (NNRT...
(Date:1/7/2009).... 7 Tiantan Puhua Hospital Stem Ce...worldwide leader in using stem cells to effectivel...x new globally experienced additions to its medica... hospital,s treatment capabilities for growing num...enior doctors include the distinguished Dr. Jiang ...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Continuous Blood Pressure Monitoring Predicts Risks 30515 1Continuous Blood Pressure Monitoring Predicts Risks 30515 2Continuous Blood Pressure Monitoring Predicts Risks 30515 311 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 111 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 211 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 311 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 411 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 511 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 611 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 7Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition 30509 1Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition 30509 2Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment 30506 1Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment 30506 2
...3, 2007 - Affymax, Inc.,(Nasdaq:AFFY) today announ...ical trials of Hematide(TM) in dialysis and,non-di...data showed,that in treatment naive, non-dialysis ...stered monthly at an appropriate dose.,Similarly, ...ith,three-times weekly Epoetin Alfa demonstrated t...
...7 - CytRx Corporation,(NASDAQ:CYTR) today announce...logy exclusively licensed to its majority-owned,su...as been,published in the April 2007 issue of peer-...The technology was developed by RXi,Co-founder, Sc...assachusetts Medical School (UMMS) Professor of Bi...
Other Medicine Technology:Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 2Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
...LY-CLARK CLOtest Rapid Urease Test is recognized b...g urease tests because of its accuracy, convenienc...y Marshall, MD. who, along with Robin Warren, M.D.... H. pylori and gastric ulcers. Today, CLOtest has ...
Serim PyloriTek Test Kit detects urease activity in gastric biopsy specimens for the presumptive identification of an Helicobacter pylori infection.
...ickVue H.pylori gII test is a lateral-flow immuno-...itative detection of IgG antibodies specific to He...blood. It utilizes a convenient, non-invasive, and...s in the diagnosis of H.pylori infection in patien...
...re HP is a visually read, qualitative immunochroma... to H. pylori, a bacterium that grows in the stoma... some gastric cancers. FlexSure HP, available for ...ides the physician with the opportunity to perform...
Medicine Products: